LFVN - Lifevantage Corp


4.91
0.110   2.240%

Share volume: 161,835
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%

$4.80
0.11
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
31%
Profitability 37%
Dept financing 12%
Liquidity 49%
Performance 26%
Company vs Stock growth
vs
Performance
5 Days
8.63%
1 Month
6.28%
3 Months
-25.61%
6 Months
-59.45%
1 Year
-69.64%
2 Year
-29.86%
Key data
Stock price
$4.91
P/E Ratio 
9.95
DAY RANGE
$4.77 - $5.02
EPS 
$0.63
52 WEEK RANGE
$3.90 - $17.64
52 WEEK CHANGE
-$68.16
MARKET CAP 
78.239 M
YIELD 
2.84%
SHARES OUTSTANDING 
12.793 M
DIVIDEND
$0.045
EX-DIVIDEND DATE
03-02-2026
NEXT EARNINGS DATE
05-01-2025
BETA 
-0.96
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$156,610
AVERAGE 30 VOLUME 
$248,864
Company detail
CEO: Steven R. Fife
Region: US
Website: lifevantage.com
Employees: 260
IPO year: 2004
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, and Singapore.

Recent news